<DOC>
	<DOCNO>NCT01704534</DOCNO>
	<brief_summary>The purpose study determine whether ustekinumab effective treatment moderate severe hidradenitis suppurativa .</brief_summary>
	<brief_title>A Proof Concept Study Evaluate Effectiveness Ustekinumab Hidradenitis Suppurativa</brief_title>
	<detailed_description>An open label prospective study perform investigate effectiveness safety ustekinumab hidradenitis suppurativa . Twenty patient include . They receive ustekinumab 45 90 mg week 0-4-16-28 . Patients follow untill week 40 .</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>18 year old Hidradenitis suppurativa Hurley stage II III No response conventional local oral antibiotic , immunnesuppressive medication , TNFalpha inhibitor surgery The patient able complete dutch questionnaire Informed consent must obtain Not able complete Dutch questionnaire Pregnancy breast feed Active hepatitis B C infection , HIV tuberculosis Treatment biologics immunosuppressive medicine previous 3 month Malignancies last 10 year exception basal cell carcinoma Demyelinating disorder Heart failure Known allergy ustekinumab preservative Live vaccins next 3 month Sever liver renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Hidradenitis suppurativa</keyword>
	<keyword>Acne ectopica</keyword>
	<keyword>Inverse acne</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>Stelara</keyword>
</DOC>